LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
ConditionNasopharyngeal Cancinoma (NPC)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorHunan Cancer Hospital
About this trial
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
Eligibility criteria
Qualifiers
Age ≥ 18 years and ≤ 70 years, male or non-pregnant female.
Histologically confirmed with nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III)
Stage IVB (AJCC 8th edition staging)
De novo nasopharyngeal carcinoma with liver metastasis, or patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion.
Disqualifiers
Patients with tumor recurrence at the primary site who have previously received radical radiotherapy.
Tumor invasion involving major blood vessels, with a high risk of significant bleeding as assessed by the investigator.
Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment.
Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4).
Trial design
Treatments tested in this trial
- Low-dose radiotherapy combine with chemoimmunotherapy
Treatment groups
26 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov